Spago’s phase I/IIa cancer study on track for 2025 completion
9 juni, 10:27
9 juni, 10:27
Spago Nanomedical has received approval to continue its phase I/IIa Tumorad-01 study with the cancer drug candidate 177Lu-SN201 at the highest current dose level, following a positive safety review. The study progresses with patient recruitment in Australia, aiming for completion of the initial phase I in 2025. We spoke with the CEO Mats Hansen for a comment.
Read the full interview at biostock.se:
https://biostock.se/en/2025/06/spagos-phase-i-iia-cancer-study-on-track-for-2025-completion/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
9 juni, 10:27
Spago Nanomedical has received approval to continue its phase I/IIa Tumorad-01 study with the cancer drug candidate 177Lu-SN201 at the highest current dose level, following a positive safety review. The study progresses with patient recruitment in Australia, aiming for completion of the initial phase I in 2025. We spoke with the CEO Mats Hansen for a comment.
Read the full interview at biostock.se:
https://biostock.se/en/2025/06/spagos-phase-i-iia-cancer-study-on-track-for-2025-completion/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/
Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!
About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.
BioStock – Connecting Innovation & Capital.
Investmentbolagen
Storbritannien
Aktieråd
VD-sortin i Rusta
Investmentbolagen
Storbritannien
Aktieråd
VD-sortin i Rusta
Idag, 11:19
Boeing-flygplan har kraschat i Indien
Idag, 08:44
Kivra ska lansera BankID-utmanare
OMX Stockholm 30
1 DAG %
Senast
2 475,62